Epidemiologic classification of human papillomavirus types associated with cervical cancer
- PMID: 12571259
- DOI: 10.1056/NEJMoa021641
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Abstract
Background: Infection with human papilloma virus (HPV) is the main cause of cervical cancer, but the risk associated with the various HPV types has not been adequately assessed.
Methods: We pooled data from 11 case-control studies from nine countries involving 1918 women with histologically confirmed squamous-cell cervical cancer and 1928 control women. A common protocol and questionnaire were used. Information on risk factors was obtained by personal interviews, and cervical cells were collected for detection of HPV DNA and typing in a central laboratory by polymerase-chain-reaction-based assays (with MY09/MY11 and GP5+/6+ primers).
Results: HPV DNA was detected in 1739 of the 1918 patients with cervical cancer (90.7 percent) and in 259 of the 1928 control women (13.4 percent). With the GP5+/6+ primer, HPV DNA was detected in 96.6 percent of the patients and 15.6 percent of the controls. The most common HPV types in patients, in descending order of frequency, were types 16, 18, 45, 31, 33, 52, 58, and 35. Among control women, types 16, 18, 45, 31, 6, 58, 35, and 33 were the most common. For studies using the GP5+/6+ primer, the pooled odds ratio for cervical cancer associated with the presence of any HPV was 158.2 (95 percent confidence interval, 113.4 to 220.6). The odds ratios were over 45 for the most common and least common HPV types. Fifteen HPV types were classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82); 3 were classified as probable high-risk types (26, 53, and 66); and 12 were classified as low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108). There was good agreement between our epidemiologic classification and the classification based on phylogenetic grouping.
Conclusions: In addition to HPV types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 should be considered carcinogenic, or high-risk, types, and types 26, 53, and 66 should be considered probably carcinogenic.
Copyright 2003 Massachusetts Medical Society
Comment in
-
Adding a test for human papillomavirus DNA to cervical-cancer screening.N Engl J Med. 2003 Feb 6;348(6):489-90. doi: 10.1056/NEJMp020178. N Engl J Med. 2003. PMID: 12571255 No abstract available.
-
Classification of human papillomavirus.N Engl J Med. 2003 May 15;348(20):2040-1; author reply 2040-1. doi: 10.1056/NEJM200305153482022. N Engl J Med. 2003. PMID: 12748326 No abstract available.
-
Type-specific testing for human papillomavirus.N Engl J Med. 2003 Aug 7;349(6):614-5. doi: 10.1056/NEJM200308073490619. N Engl J Med. 2003. PMID: 12904531 No abstract available.
Similar articles
-
[Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities].Mikrobiyol Bul. 2008 Apr;42(2):273-82. Mikrobiyol Bul. 2008. PMID: 18697425 Turkish.
-
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.J Natl Cancer Inst. 2006 Mar 1;98(5):303-15. doi: 10.1093/jnci/djj067. J Natl Cancer Inst. 2006. PMID: 16507827
-
HPV types and cofactors causing cervical cancer in Peru.Br J Cancer. 2001 Sep 28;85(7):966-71. doi: 10.1054/bjoc.2001.1948. Br J Cancer. 2001. PMID: 11592767 Free PMC article.
-
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer.N Engl J Med. 1999 Nov 25;341(22):1633-8. doi: 10.1056/NEJM199911253412201. N Engl J Med. 1999. PMID: 10572150
-
Human papillomavirus and cancer: the epidemiological evidence.J Clin Virol. 2000 Oct;19(1-2):1-5. doi: 10.1016/s1386-6532(00)00125-6. J Clin Virol. 2000. PMID: 11091143 Review.
Cited by
-
Prevalence of human papillomavirus (HPV) in oesophageal squamous cell carcinoma in relation to anatomical site of the tumour.PLoS One. 2012;7(10):e46538. doi: 10.1371/journal.pone.0046538. Epub 2012 Oct 12. PLoS One. 2012. PMID: 23077513 Free PMC article.
-
Co-expression of SOX2 and HR-HPV RISH predicts poor prognosis in small cell neuroendocrine carcinoma of the uterine cervix.BMC Cancer. 2021 Mar 31;21(1):332. doi: 10.1186/s12885-021-08059-1. BMC Cancer. 2021. PMID: 33789601 Free PMC article.
-
Long-read sequencing reveals the structural complexity of genomic integration of HPV DNA in cervical cancer cell lines.BMC Genomics. 2024 Feb 20;25(1):198. doi: 10.1186/s12864-024-10101-y. BMC Genomics. 2024. PMID: 38378450 Free PMC article.
-
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.ISRN Obstet Gynecol. 2011;2011:457204. doi: 10.5402/2011/457204. Epub 2011 Nov 2. ISRN Obstet Gynecol. 2011. PMID: 22111017 Free PMC article.
-
Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination.Hum Vaccin Immunother. 2024 Dec 31;20(1):2392330. doi: 10.1080/21645515.2024.2392330. Epub 2024 Sep 6. Hum Vaccin Immunother. 2024. PMID: 39238340 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous